Eribulin Mesylate: Clinical Trials

77 trials of Eribulin Mesylate, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

47 completed, 10 unknown, 9 terminated, 7 active not recruiting. 45 Phase 2, 26 Phase 1, 5 Phase 3, 3 Phase 4, 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 245Completed 28, Unknown 8, Terminated 5, Active not recruiting 3, Recruiting 1
Phase 126Completed 14, Terminated 8, Active not recruiting 3, Withdrawn 1
Phase 35Active not recruiting 3, Completed 1, Suspended 1
Phase 43Completed 3
Early Phase 11Completed 1
Not applicable1Completed 1

Follow Eribulin Mesylate: new trials by email Literature Review of Eribulin Mesylate trials Research Report on Eribulin Mesylate

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Phase 1WithdrawnNational Cancer Institute (NCI)2025-08-042025-07-03
Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial
Eribulin, Sintilimab - Metastatic Breast Cancer
Phase 2UnknownZhejiang Cancer Hospital812024-03-082024-03-13
EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Eribulin Mesylate, Pembrolizumab - Ovarian Carcinosarcoma, Uterine Carcinosarcoma
Phase 2CompletedAustralia New Zealand Gynaecological Oncology Group132023-05-222026-08-06
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
Dato-DXd, Paclitaxel, Nab-paclitaxel - Breast Cancer
Phase 3Active not recruitingAstraZeneca6442022-05-162026-05-15
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
Eribulin Mesylate, Grapiprant - Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center62021-12-212025-06-13
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Dato-DXd, Capecitabine, Gemcitabine - Breast Cancer
Phase 3Active not recruitingAstraZeneca7322021-10-182026-08-24
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
Biospecimen Collection, Bone Scan, Computed Tomography - Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Phase 3Active not recruitingNational Cancer Institute (NCI)1312021-06-282026-11-12
Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients
Eribulin Mesylate - Triple Negative Breast Cancer
Phase 2UnknownThe First Affiliated Hospital with Nanjing Medical University1002021-06-012020-08-11
Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer
Eribulin Mesylate, Anlotinib hydrochloride - HER2-negative Breast Cancer
Phase 2UnknownThe First Affiliated Hospital with Nanjing Medical University402021-03-012021-05-21
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Phase 1 / Phase 2Active not recruitingNational Cancer Institute (NCI)242021-03-012026-11-18
Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer
Eribulin Mesylate, Anlotinib - Metastatic Breast Cancer
Phase 2CompletedHunan Cancer Hospital802020-10-092022-11-23
Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer
Eribulin Mesylate, Lobaplatin - Triple Negative Breast Cancer
Phase 2UnknownChinese Academy of Medical Sciences402020-06-012022-09-19
A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC
Camrelizumab, Apatinib, Eribulin - Breast Cancer
Phase 2UnknownSun Yat-Sen Memorial Hospital of Sun Yat-Sen University462020-03-252023-04-12
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar), Eribulin Mesylate - Advanced Breast Cancer
Phase 2RecruitingSeoul National University Hospital1802020-02-182025-11-20
Breast Cancer Treatment Based on Organ-like Culture
Trastuzumab, Doxorubicin Hydrochloride, Epirubicin hydrochloride - Breast Cancer Organoids
UnknownXijing Hospital3002019-01-022019-04-24
Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients
Eribulin Mesylate, Capecitabine - Metastatic Breast Cancer
Phase 2UnknownConsorzio Oncotech1222018-07-302023-04-27
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
Atezolizumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)722018-07-202026-11-18
A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Eribulin Mesylate, Avelumab - Metastatic Urothelial Cell Cancer
Phase 1TerminatedMonika Joshi, MD62018-06-122022-07-01
M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
Bintrafusp Alfa, Eribulin Mesylate - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Phase 1TerminatedM.D. Anderson Cancer Center382018-05-302022-10-31
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Eribulin mesylate - Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma
Phase 2CompletedEisai Inc.232018-04-172022-10-05

Showing 20 of 77. Sign in to see all of them.

Conditions studied

Breast Neoplasms (37)  ·  Neoplasms (8)  ·  Triple Negative Breast Neoplasms (8)  ·  Neoplasm Metastasis (5)  ·  Sarcoma (3)  ·  Urinary Bladder Neoplasms (3)  ·  Brain Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Carcinoma, Transitional Cell (2)  ·  Lymphoma (2)  ·  Ureteral Neoplasms (2)  ·  Urethral Neoplasms (2)  ·  Breast Neoplasms, Male (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Drug-Related Side Effects and Adverse Reactions (1)

Sponsors

Eisai Inc. (17)  ·  National Cancer Institute (NCI) (15)  ·  Eisai Co., Ltd. (4)  ·  Eisai Limited (4)  ·  AstraZeneca (2)  ·  City of Hope Medical Center (2)  ·  Dana-Farber Cancer Institute (2)  ·  Eisai Korea Inc. (2)  ·  M.D. Anderson Cancer Center (2)  ·  The First Affiliated Hospital with Nanjing Medical University (2)  ·  University of Washington (2)  ·  Academic and Community Cancer Research United (1)  ·  Australia New Zealand Gynaecological Oncology Group (1)  ·  Case Comprehensive Cancer Center (1)  ·  Chang Gung Memorial Hospital (1)

Countries

United States (47)  ·  Canada (10)  ·  China (9)  ·  United Kingdom (7)  ·  Italy (6)  ·  Japan (6)  ·  France (5)  ·  Germany (5)  ·  South Korea (5)  ·  Spain (5)  ·  Taiwan (5)  ·  Belgium (4)  ·  Netherlands (4)  ·  Argentina (3)  ·  Brazil (3)

Top investigators

Sam Misir (3)  ·  Sarmad Sadeghi (2)  ·  Amanda Linz, MD (1)  ·  Anishka A D'Souza (1)  ·  Barbara Gitlitz (1)  ·  Clare Scott, AM MB BS PhD (1)  ·  David I Quinn (1)  ·  Dr. Claudio Savulsky (1)  ·  Giovanna Damia, PHD (1)  ·  Hannah Linden (1)  ·  Harish Dave (1)  ·  Heather Han, M.D. (1)  ·  Hiroshi Obaishi (1)  ·  Jana Portnow, MD (1)

Results publications

PMID 20299316, PMID 21935916, PMID 24699910, PMID 25605862, PMID 26006067, PMID 26126970, PMID 26554651, PMID 26567010, PMID 27391598, PMID 27398025, PMID 28660549, PMID 30783204, PMID 31365116, PMID 31390274, PMID 31703728, PMID 32827353, PMID 32880602, PMID 33741296, PMID 34302589, PMID 34548479, PMID 35546669, PMID 35641481, PMID 36307826, PMID 37387213, PMID 37526149, PMID 39265124, PMID 39422741, PMID 42501677

NIH funding

2009 (3), U01CA062505 (3), 2023 (2), N01CM00038 (2), N01CM62201 (2), N01CM62209 (2), P30CA033572 (2), UM1CA186717 (2), 2015 (1), N01CM00032 (1), N01CM00071 (1), N01CM17107 (1), N01CM62203 (1), N01CM62204 (1), N01CM62206 (1)